HYDERABAD, India — Dr. Reddy’s Laboratories has launched divalproex sodium extended-release tablets, an anti-seizure medication, in the U.S. market after receiving approval from the Food and Drug Administration.

The company said its divalproex sodium ER product, available in strengths of 250 mg and 500 mg, is a therapeutic equivalent generic version of AbbVie Inc.’s Depakote ER tablets.

Dr. Reddy’s divalproex sodium ER tablets come in a 100-count size for the 250-mg dosage and 100-count and 500-count sizes for the 500-mg dosage.

Divalproex sodium treats various types of seizure disorders and may be used along with other seizure medications. The medication also is used to treat manic episodes from bipolar disorder (manic depression) and to prevent migraine headaches.

Depakote ER brand and its generics had total U.S. sales of about $194 Million MAT for the 12 months ended in June, according to IMS Health data reported by Dr. Reddy’s.